10-Q: Celularity Faces Delisting, Deepening Losses Amid Liquidity Crisis

Celularity Inc. reported significant losses and a going concern warning for Q2 2025, alongside Nasdaq delisting threats and multiple legal challenges.

Summary

• Reported a net loss of $44.278 million for the six months ended June 30, 2025, an increase from $28.501 million in the prior year period.
• Total net revenues decreased by 35.9% to $17.162 million for the six months ended June 30, 2025, primarily due to a 50.0% decrease in product sales.
• Operating loss for the six months ended June 30, 2025, increased by 50.1% to $26.350 million.
• Accumulated deficit reached $944.025 million as of June 30, 2025.
• Received a Nasdaq notice of non-compliance for failing to timely file its Form 10-Q, with an extension granted until August 31, 2025, to regain compliance.
• Substantial doubt exists about the company's ability to continue as a going concern due to significant operating losses, insufficient cash, and reliance on additional capital.
• Engaged in multiple capital raising activities and debt modifications, including private placements and merchant cash advances, to address liquidity needs.
• Sold certain intellectual property to Celeniv Pte. Ltd. for $33.812 million to fully repay the RWI Bridge Loan and a promissory note to Lim Kok Thay.
• Identified material weaknesses in internal control over financial reporting, with a remediation plan underway.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by widening losses, negative equity, a going concern warning, and Nasdaq delisting threats. While there are some operational updates and capital raises, these are primarily defensive measures to address immediate liquidity issues rather than indicators of strong growth or stability. The termination of a key collaboration and multiple legal defaults further underscore the precarious situation.

Positives

• Net cash used in operating activities decreased to $3.992 million for the six months ended June 30, 2025, from $7.851 million in the prior year period, indicating improved operational cash burn.
• Research and development expenses decreased by 26.6% to $7.080 million for the six months ended June 30, 2025, reflecting reprioritization efforts.
• Selling, general and administrative expenses decreased by 10.2% to $26.896 million for the six months ended June 30, 2025.
• Successfully secured multiple debt extensions and capital raises, including a $2.46 million warrant exercise by Dragasac and a $1.035 million private placement, providing short-term liquidity.
• Acquired Sequence LifeScience's Rebound full thickness placental-derived allograft matrix product, expanding the biomaterials portfolio.
• Maintains a robust global intellectual property portfolio with over 290 patents and patent applications.

Negatives

• Net loss significantly widened to $44.278 million for the six months ended June 30, 2025, compared to $28.501 million in the prior year.
• Total net revenues decreased by 35.9% to $17.162 million for the six months ended June 30, 2025, primarily due to a 50.0% decline in product sales.
• Cost of revenues increased by 134% to $8.796 million for the six months ended June 30, 2025, including a $2.5 million write-off of capitalized bulk material costs and a $1.5 million milestone accrual for Rebound.
• Accumulated deficit reached $944.025 million as of June 30, 2025, highlighting substantial historical losses.
• Total stockholders' (deficit) equity turned negative at $(25.497) million as of June 30, 2025, from positive $8.837 million at December 31, 2024.
• Received a Nasdaq notice of non-compliance for late filing of the Form 10-Q, with a risk of delisting if compliance is not regained by August 31, 2025.
• Substantial doubt about the ability to continue as a going concern, indicating severe liquidity challenges and potential inability to meet obligations.
• Outstanding debt of approximately $6.3 million is due within one year, with a substantial portion under forbearance agreements, posing a risk of asset seizure or liquidation if terms are not met.
• The Regeneron research collaboration services agreement was terminated by Regeneron on August 6, 2025, impacting future deferred revenue recognition.
• Multiple legal proceedings are ongoing, including claims for unpaid invoices and alleged breach of contract, with judgments already entered against the company in some cases.
• Identified material weaknesses in internal control over financial reporting, indicating deficiencies in financial reporting processes.

Risks

• Substantial doubt about the ability to continue as a going concern, potentially affecting future financing and requiring curtailment of operations or bankruptcy.
• Inability to obtain additional funding on acceptable terms or at all, leading to delays, limitations, or termination of operations, workforce reductions, or liquidation.
• Risk of delisting from Nasdaq due to non-compliance with timely filing requirements, which could materially adversely affect the ability to continue as a going concern.
• Lenders may exercise rights and remedies under loan agreements, including seizing assets or forcing liquidation, if forbearance agreement terms are not met or debt is not repaid.
• Significant decline in sales of commercialized biomaterial products could severely harm the business.
• Challenges in developing placental-derived cellular therapy candidates, which represent a novel approach to disease treatments.
• Inability to obtain regulatory approval for lead therapeutic candidates, preventing or delaying commercialization.
• Reliance on third-party distribution arrangements for biomaterials products, with risks of unmet demand or costs for unmaterialized forecasts.
• Potential impact on commercial biomaterials business if regulatory authorities determine certain products do not qualify for reimbursement (e.g., Interfyl claims rejected by CMS).
• Reliance on third parties to conduct future clinical trials, with risks if they do not meet contractual duties or deadlines.
• Lengthy and time-consuming FDA regulatory approval process, potentially causing significant delays.
• Inability to file Investigational New Drug (IND) applications on expected timelines or FDA not permitting trials without additional information.
• Manufacturing or other failures at the company's own facility could adversely affect clinical trials and commercial viability.
• Inability to successfully leverage core expertise in contract manufacturing and development services to third parties.
• Dependence on donors of healthy human full-term post-partum placentas for manufacturing, with risks if supply is inadequate.
• Potential failure of future clinical trials to demonstrate safety and/or efficacy of therapeutic candidates.
• Inadequate protection of intellectual property, affecting competitive effectiveness.
• Disputes with third parties regarding agreements, potentially leading to additional payments or litigation costs.
• Therapeutic candidates may cause undesirable side effects, halting development or limiting commercial potential.
• Significant competition from other biotechnology and pharmaceutical companies.
• Exposure to numerous laws and regulations regarding relationships with customers, physicians, and third-party payors, with risks of substantial penalties for violations.
• Adverse effects from health pandemics, geopolitical conflicts, inflation, bank failures, and recessions.
• Continued significant costs of operating as a public company and management time devoted to compliance initiatives.
• Uncertainty regarding the impact of the One Big Beautiful Bill Act (OBBBA) on deferred tax balances and financial statements.

Future Outlook

The company expects to continue incurring significant operating losses and using net cash for operations for the foreseeable future. It will need to secure additional outside capital to fund investments and meet obligations. The company plans to submit a 510(k) application for Celularity Tendon Wrap (CTW) in the second half of 2025, advance FUSE Bone Void Filler for a 510(k) filing in the second half of 2026, and Celularity Placental Matrix (CPM) for a 510(k) filing in the second half of 2027. Opportunities in Florida and elsewhere to supply MLASCs cell therapy product candidates PDA 001 and PDA 002 are being assessed. The company also plans to complete safety and efficacy assessments for PDA 001 in Crohn's disease and PDA 002 in DFU for potential Phase III clinical trials, contingent on sufficient capitalization. The Regeneron Services Agreement was terminated, with remaining deferred revenue to be recognized in Q3 2025.

Management Comments

• "We expect to continue to incur significant operating losses and use net cash for operations for the foreseeable future."
• "Absent the ability to secure additional outside capital in the very near term, we will be unable to meet our obligations as they become due over the next 12 months beyond the issuance date."
• "Management will be required to seek other strategic alternatives, which may include, among others, a significant curtailment of our operations, a sale of certain of our assets, a sale of our entire company to strategic or financial investors, and/or allowing us to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy Code."
• "Our current science is the product of the cumulative background and effort over two decades of our seasoned and experienced management team."
• "We believe this know-how, expertise and intellectual property will drive the rapid development and, if approved, the commercialization of these potentially lifesaving therapies for patients with unmet medical needs."
• "We expect that as a result of our reprioritization efforts, we will see a decrease in our selling, general and administrative costs in the near term."
• "To date, inflation has not had a significant impact on our business. However, any significant increase in inflation and interest rates could have a significant effect on the economy in general and, thereby, could affect our future operating results."

Industry Context

The biotechnology industry, particularly in cell therapy and regenerative medicine, is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Celularity's focus on placental-derived therapies represents a novel approach, but also significant challenges in a field where many candidates fail clinical trials. The company's financial distress and reliance on continuous capital raises are common for early-stage biotech firms, but the magnitude of losses and the Nasdaq delisting threat indicate a more severe situation than many peers. The mention of new state legislation expanding access to stem cell therapies (e.g., Florida) suggests a potential, albeit limited, market opportunity for unapproved treatments, which could be a strategic pivot for companies facing traditional regulatory hurdles.

Comparison to Industry Standards

• Celularity's accumulated deficit of $944.025 million and negative stockholders' equity of $(25.497) million are significantly worse than industry averages for established biotech companies and indicate a highly distressed financial position compared to peers like Organogenesis Holdings Inc. (ORGO) or Vericel Corporation (VCEL) which have positive equity and are generating profits from commercialized regenerative medicine products.
• The substantial doubt about continuing as a going concern is a critical red flag, placing Celularity far below the financial stability of most publicly traded biotechnology companies, which typically maintain sufficient cash reserves or clear paths to funding for at least 12-18 months.
• The Nasdaq delisting threat for late filings is a severe governance and operational issue, contrasting sharply with the compliance standards expected of public companies in the biotech sector, where timely and accurate reporting is paramount for investor confidence.
• While Celularity's pipeline for biomaterial products (CTW, FUSE, CPM) and cell therapies (PDA 001, PDA 002) shows activity, the lack of approved cellular therapeutic products and the termination of the Regeneron collaboration indicate slower progress and less commercial traction compared to more advanced cell therapy developers like Kite Pharma (Gilead subsidiary) or Novartis's Kymriah, which have FDA-approved products generating significant revenue.
• The company's reliance on frequent, dilutive capital raises and asset sales to cover operational expenses and debt repayments is a sign of financial weakness, unlike more mature biotech firms that can fund R&D through product sales or less dilutive financing options.

Corporate Governance

Legal Proceedings

• Received a Civil Investigative Demand under the False Claims Act from the U.S. Attorney's Office for the Eastern District of Pennsylvania, requesting documents related to claims submitted to federal insurers for injectable human tissue therapy products, including Interfyl. The matter is in preliminary stages with uncertain liability.
• Filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, and Encyte, LLC to recover approximately $2.35 million in unpaid invoices for biomaterial products, alleging breach of contract and fraudulent inducement. Evolution filed a counterclaim for damages.
• WMBE Payrolling, Inc., dba TCWGlobal, filed a complaint for breach of contract and account stated claims for services of leased workers. A settlement agreement for $516,000 was reached, but the company defaulted on payments in November 2024. A motion to enforce settlement and enter judgment for $350,000 was granted by the Court on June 3, 2025.
• Hackensack Meridian Health (HUMC) filed a complaint seeking $946,000 for clinical trial costs, with the company asserting improper charges. The agreed amount owed is $668,000, which has been accrued. HUMC has moved for entry of default.
• Clinical Resource Network (CRN) filed a complaint seeking $176,000 for unpaid invoices for payrolling services. The company defaulted, and CRN moved for entry of default on July 23, 2025.

Related Party Transactions

• Dr. Robert Hariri, Chairman and CEO, temporarily reduced his salary to minimum wage in January 2023, with the remainder deferred. A bonus program was approved in February 2024 for 125% of unpaid base salary upon certain conditions. His base salary resumed on January 1, 2025.
• Dr. Robert Hariri entered into a $1.0 million loan agreement with the company on August 21, 2023, and a $285,000 promissory note on October 12, 2023. He assumed loans from two unaffiliated lenders on September 30, 2024, and extended the maturity date of his loans to December 31, 2025.
• C.V. Starr & Co., Inc., a stockholder, provided a $5.0 million Starr Bridge Loan on March 17, 2023, and additional warrants in June 2023. The loan was fully repaid on July 29, 2025.
• Resorts World Inc Pte Ltd (RWI), a related party, provided the RWI Bridge Loan and Amended RWI Loan, and the RWI Second Amended Bridge Loan. These loans were fully satisfied on August 13, 2025, through an asset purchase agreement with Celeniv Pte. Ltd. (an assignee of Lim Kok Thay, who received a promissory note from the company).
• Alexandra Hariri, daughter of Dr. Robert J. Hariri, is employed as Executive Director, Corporate Strategy & Business Development, with an annual base salary of $265,000 for 2025 and 2024, and is eligible for bonuses, equity awards, and benefits on similar terms as other employees.
• The company entered into a Technology Services Agreement with Fountain Life Management LLC, whose founding partners include Dr. Robert Hariri and director Peter Diamandis. Fountain Life will pay a one-time fee of $2,500 per sample collected and stored.
• Dragasac Limited, an existing investor and affiliate of Genting Berhad, participated in a $6.0 million private placement in January 2024 and had legacy warrants repriced. The company also has a distribution and manufacturing agreement with Genting Innovation Pte Ltd, a direct subsidiary of Genting Berhad.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from ongoing capital raises and warrant exercises. The negative stockholders' equity and Nasdaq delisting threat pose substantial risks to investment value. The asset sale, while repaying debt, reduces the company's asset base.
• **Employees**: Workforce reductions are a potential strategic alternative if additional capital is not secured. Stock-based compensation remains a component of remuneration, but the declining share price and financial instability could impact its value.
• **Customers**: The termination of the Regeneron agreement could impact future service offerings. For biobanking and degenerative disease products, continued operations depend on securing funding, which could affect service continuity or product availability.
• **Suppliers/Creditors**: Multiple legal proceedings for unpaid invoices and defaults on debt obligations indicate high credit risk. Lenders under forbearance agreements face the risk of asset seizure or liquidation if terms are not met.
• **Regulatory Bodies (Nasdaq, SEC)**: The company is under scrutiny for non-compliance with Nasdaq listing rules and has identified material weaknesses in internal controls, requiring significant remediation efforts and ongoing monitoring.

Next Steps

• File the Form 10-Q for periods ended March 31, 2025, and June 30, 2025, by August 31, 2025, to regain Nasdaq compliance.
• Continue implementing the remediation plan to address material weaknesses in internal control over financial reporting.
• Submit a 510(k) application for Celularity Tendon Wrap (CTW) in the second half of 2025.
• Advance the development of FUSE Bone Void Filler with the objective of a 510(k) filing in the second half of 2026.
• Advance the development of Celularity Placental Matrix (CPM) with the objective of a 510(k) filing in the second half of 2027.
• Actively assess opportunities in Florida and elsewhere to supply MLASCs cell therapy product candidates PDA 001 and PDA 002 to physicians in accordance with state law.
• Complete safety and efficacy assessment to determine progress to a Phase III clinical trial of PDA 001 in Crohn's disease and PDA 002 in DFU, contingent on sufficient capitalization.
• Evaluate all deferred tax balances under the newly enacted tax law (OBBBA) and identify any other required changes to financial statements for the quarter ended September 30, 2025.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, marked by widening net losses, negative stockholders' equity, and an explicit 'going concern' warning. The Nasdaq delisting threat due to late filings, coupled with multiple legal defaults and an asset sale to repay debt, indicates a critical liquidity crisis and significant operational and governance failures. While the company is actively pursuing capital raises, these appear to be defensive measures to stave off insolvency rather than funding for robust growth. The termination of a key collaboration (Regeneron) further diminishes future revenue prospects. Given the high risk of delisting, potential bankruptcy, and ongoing financial deterioration, the stock carries extreme risk, making it an unsuitable investment for most investors.

Keywords

Cell Therapy, Regenerative Medicine, Biomaterials, Placental-derived, Biobanking, Oncology, Degenerative Disease, Wound Care, SEC Filing, 10-Q, Biotechnology, Clinical Trials, Nasdaq Delisting, Going Concern, Liquidity, Capital Raise, Financial Performance, Intellectual Property